Kestra Medical Technologies (KMTS) Liabilities and Shareholders Equity (2024 - 2026)

Kestra Medical Technologies (KMTS) has reported Liabilities and Shareholders Equity for 3 consecutive years, with $358.5 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity rose 21.21% year-over-year to $358.5 million; the TTM figure through Apr 2026 stood at $1.3 billion (up 209.81% YoY), while the FY2026 annual figure was $358.5 million, up 21.21% from the prior year.
• Liabilities and Shareholders Equity eased to $358.5 million in Q2 2026 per KMTS's latest filing, from $379.3 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $379.3 million in Q1 2026 and bottomed at $45.9 million in Q2 2024.
• Historically, Liabilities and Shareholders Equity has averaged $242.9 million across 3 years, with a median of $266.3 million in 2025.
• Annual changes were most pronounced in 2025 — Liabilities and Shareholders Equity surged 543.64% — and 2026, when it advanced 21.21%.
• Kestra Medical Technologies' Liabilities and Shareholders Equity stood at $45.9 million in 2024, then surged by 436.9% to $246.7 million in 2025, then jumped by 45.3% to $358.5 million in 2026.
• Business Quant data shows KMTS's Liabilities and Shareholders Equity at $358.5 million in Q2 2026, $379.3 million in Q1 2026, and $246.7 million in Q4 2025.